RxDoctor Payments Data

Glorimar Caldera Alvarado, MD

Gastroenterology · Little River, SCNPI 1275935256

Payments from drug & device makers

$7,106in general payments, 2019–2025

Across 162 payments — averaging $43.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Eli Lilly$1K
  • AbbVie$1K
  • Merck$323
  • Sanofi$209
  • Johnson & Johnson$208
  • plus $1K from 22 others
$126in research payments, 2019–2025

Across 2 payments — averaging $63.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$126

What the payments were for

  • Travel & lodging$97220%
  • Food & beverage$3,84679%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,106 in reported general payments places this provider in the 65th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$157,856
Medicare patients
646
Services billed
1,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$44,662
LinzessLinaclotide14$19,533
Mesalamine16$7,428
Omeprazole211$4,359
Esomeprazole Magnesium41$3,430
CholestyramineCholestyramine (With Sugar)17$2,133
Pantoprazole Sodium112$2,115
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,112
Lubiprostone11$1,772
Dicyclomine Hcl61$1,707
Famotidine117$1,362
Azathioprine13$673
Ondansetron OdtOndansetron32$419
Metronidazole15$56
Prednisone18$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,268$64,19533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →